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Proteins destined for secretion in both prokaryotic and eukaryotic organisms are initially synthesized as precursors with an amino-terminal extension known as signal (or leader) peptide. The signal sequence is removed by a SPase that is localized in the cytoplasmic membrane in bacteria. Cleavage of precursors by SPase leads to the release of secreted proteins from the outer surface of cytoplasmic membrane. In bacteria, two major SPases, SPase I and SPase II with different cleavage specificities, have been identified. SPase I is responsible for processing majority of secreted proteins (1) (2) (3) , and SPase II is exclusively involved in processing glyceride-modified lipoproteins (4) .
SPase I is an attractive target for development of anti-bacterial agents because of its unique biochemical and physiological properties. It is essential for bacterial viability and growth as demonstrated by gene knockout and other genetic experiments (5) (6) (7) (8) . It is widely distributed in both Gram-positive and Gram-negative bacteria, as well as in Chlamydia. Genes encoding SPase I have been cloned and sequenced from different bacterial species, including many of clinically relevant bacteria (8, 9) . The active domain of bacterial SPase I is exposed to the surface of cytoplasmic membrane as revealed by sequence and topological analysis (10) (11) (12) , and thus is accessible to potential inhibitors.
In addition, SPases from bacteria and eukaryotic cells are different in composition, location and possibly catalytic mechanism (13-17). These differences make it possible to identify selective bacterial SPase I inhibitors without toxicity to mammalian cells.
SPase I belongs to a novel class of serine protease that utilizes a serine and a lysine to form a unique catalytic dyad for peptide hydrolysis (14) (15) (16) . Because of this unique catalytic mechanism, they are not sensitive to the classic protease inhibitors (2, 3, 18) .
The first effective inhibitor of bacterial SPase I was described in 1994 by Kuo and colleagues, who reported that β-lactams could inhibit E. coli SPase I in a pH-and timedependent manner (19) . Certain β-lactams have also been shown to be effective irreversible inhibitors of a number of serine proteases and hydrolases, such as elastase (20, 21) , phospholipase A2 (22) , and β-lactamase (23) . Researchers at Smith Kline
Beecham have extensively studied β-lactam (or penem)-type inhibitors against E. coli SPase I (24, 25) . To our knowledge, allyl (5S, 6S)-6-((R)-acetoxyethyl)-penem -3-carboxylate (5S, 6S-penem) is one of the most potent inhibitors of E. coli SPase I reported thus far.
In previous studies, we cloned the gene encoding SPase I of S. pneumoniae and identified the precursor of streptokinase as a native substrate of the enzyme (9) . Consequently, we developed a fluorescent peptide substrate, KLTFGTVK(Abz)PVQAIAGY(NO2)EWL and a continuous fluorimetric assay for this enzyme (26) . In this report we identify a family of novel lipoglycopeptides from a microbial source, which are potent inhibitors of bacterial SPase I and are able to inhibit the growth of clinically relevant bacteria.
EXPERIMENTAL PROCEDURES
Bacterial strains -S. pneumoniae R6 was an unencapsulated D39 derivative (27, 28) . S.
aureus ATCC 33592 was a gentamicin and methicillin-resistant, β-lactamase-producing strain (29) . Haemophilus influenzae ATCC 49247 and S. aureus ATCC 13709 were commonly used bacterial strains for MIC studies. E. coli K12, EL683 (K12MG1655, envA1 zac3051::Tn10) and EL744 (K12MG1655, ∆tolC::kan r ) were from our laboratory collection. Streptomyces sp. utilized for lipoglycopeptide production was deposited in ATCC (ATCC PTA-3546).
Purification of S. pneumoniae SPase I -Recombinant S. pneumoniae SPase I was purified as described previously (9) .
Purification of E. coli SPase I -The gene encoding E. coli SPase I was cloned by PCR.
Two primers, 5'-GATCGTTCATATGGTTCGTTCATTTCTTTATGAACCCTTTCAG-3' and 5'-GCCGCTAACTCGAGGGCAGCGTGAACGATCATTTCATCACAG-3', were synthesized according to the published sequence (10, 11) . Expression vector pET15b-EcoliSPase was constructed by replacing NdeI and XhoI fragment of pET15b with the PCR fragment. For expression of E. coli SPase I, E. coli strain BL21(DE3) was transformed with pET15b-EcoliSPase, grown and induced with IPTG as described (30) .
Since overexpressed E. coli SPase I was aggregated in inclusion body, the purification went through a denaturing and refolding process. Typically, 1 liter of IPTG-induced E. coli BL21(DE3) cells harboring pET15b-EcoliSPase were resuspended in 50 ml of lysis buffer containing 50 mM Na 2 HPO 4 , 300 mM NaCl, pH8.0, and sonicated for 5 min on ice. The lysate was centrifuged at 50,000g for 1 h at 4°C. The resultant pellet was then sonicated for 5 min in 20 ml of denaturing buffer containing 50 mM Na 2 HPO 4 , 300 mM NaCl, and 8 M urea. After centrifugation at 50,000g for 1 h at 4°C, the supernatant was loaded onto a 5 ml of pre-equilibrated Ni-nitrilotriacetic acid column that was then washed with 120 ml of refolding buffer (50 mM NaH 2 PO4, 300 mM NaC1, 15 mM imidazole) containing a continuous urea gradient from 6 to 1 M with a flow rate of 1 ml/min. The protein was finally eluted with 30 ml of elution buffer (20 mM Tris.HCl, pH 8.0, 20% glycerol, 1 M urea and 100 mM imidazole), and 1 ml fractions were collected and analyzed by SDS-PAGE. We found that 1 M urea in the elution buffer increased the recovery of active enzyme, and did not influence the enzymatic activity (data not shown).
HPLC analysis of peptide substrate cleavage by S. pneumoniae and E. coli SPase IPreviously described peptide substrates, KLTFGTVKPVQAIAGYEWL and KLTFGTVK(Abz)PVQAIAGY(NO2)EWL, were utilized for HPLC analysis (26) .
Typically, cleavage assay was performed in 50 µl reaction mixture containing 20 mM Tris-HCl, pH 8.0, 50 µg of E.coli lipid extract, 0.05 µM SPase I and 100 µM substrate.
Reaction was incubated at 37°C for 30 min and terminated by addition of an equal amount of 8 M urea. Cleavage of peptide substrate was determined by HPLC using a Hewlett Packard Series 1100 system equipped with an autosampler.
Fermentation:
An aliquot (100 µl) of Streptomyces culture (ATCC PTA-3546) was inoculated into 20 ml of a vegetative medium (31) and incubated at 30°C at 165 rpm.
After 72 h, 2 ml of the vegetative culture was transferred to 800 ml of fermentation medium (31) , incubated at 30°C at 250 rpm, and harvested after 96 h.
Isolation of lipoglycopeptides -The cell pellet from 32 liters of broth was extracted 2 X with 5 liters of CH 3 OH. The combined extracts were concentrated to 500 ml and partitioned with 500 ml of CH 3 OH and 2 X 1 liter of EtOAc. The combined EtOAc layers were evaporated (49 g), suspended in 300 ml of 3:1 (v/v) CH 3 OH-H 2 O and filtered. The filtrate was diluted with 600 ml of H 2 O and applied onto a 500 ml of TosoHaas Amberchrom CG161m column equilibrated with 3:1 (v/v) H 2 O-CH 3 OH. The column was sequentially eluted with 4 X 500 ml of 3:1 (v/v) H 2 O-CH 3 OH, 4 X 500 ml of 1:1 (v/v) H 2 O-CH 3 OH, and 8 X 500 ml of CH 3 OH. The first 2 liters of CH 3 OH effluent were concentrated (2 g) and chromatographed over a Sephadex LH-20 column (7.5 X 39 cm, Pharmacia) with CH 3 OH as the solvent. The effluent containing the lipoglycopeptides was evaporated (960 mg) and further chromatographed over a Waters SymmetryPrep C 18 column (50 X 250 mm, 7 micron, flow rate 45 ml/min, 35-70% CH 3 CN gradient buffered with 0.05% NH 4 OAc over 48 min and holding at 70% CH 3 CN for 24 min). 45 ml of fractions were collected and combined to yield three fractions A (172 mg), B (370 mg), and C (128 mg). Amino acid analysis -Amino acid analysis of lipoglycopeptide 1 was performed as described (32) .
Deacylation of lipoglycopeptides 7 and 8 -A solution containing mostly lipoglycopeptides 7 and 8 (200 mg) in 20 ml of CH 3 CN-H 2 O-TFA (6:3:1) was stirred for 90 h at room temperature. The mixture was purified over a PolyLC polyhydroxyethyl aspartamide column (50.8 X 250 mm, 12 micron, flow rate 45 ml/min, 90-50% CH 3 CN gradient buffered with 0.05% NH 4 OAc over 72 min) to yield two fractions. These fractions were further purified independently over a CG161 column (85 ml) to yield 10.7 and 14 mg of glicopeptides 9 and 10, respectively. 
LC-MS Study

Determination of in vitro anti-bacterial activity -
RESULTS
Production and purification of lipoglycopeptides -To identify novel inhibitors of
bacterial SPase I, 50,000 pre-fractionated natural product samples were screened in a high-throughput screen using the fluorimetric assay (26) . This led to the identification of a single sample derived from a microbial source with reproducible activity. Further fractionation of limited amounts of this sample resulted in the identification of two isomeric components responsible for the activity. UV-VIS and MS-based literature searches revealed that the active components might be novel. To fully characterize and study their antibiotic properties, we undertook a large-scale fermentation. Fermentation followed by chromatographic purification resulted in the isolation of eight closely related Table 1 were obtained after a detailed analysis of 1 H, 13 C, DQCOSY, TOCSY, HSQC, and HMBC, which revealed the presence of four common amino acid residues, i.e. glycine, two alanines, and N-methylserine, in addition to two uncommon aromatic amino acid residues, i.e. a 3-substituted tyrosine and a 3, 4, 5-trisubstituted N-methylphenylglycine. Consistent with this observation, the amino acid analysis revealed presence of glycine and alanine in the ratio 1:2.
The other prominent features in the NMR spectra of lipoglycopeptide 1 included resonances for a 6-deoxy sugar and a fatty acyl chain. In accordance with the proposed molecular formula and MS/MS, the number of carbons in the acyl chain was determined to be 16 ( Fig. 1, Fig. 2) . Further, the NMR spectrum suggested that the acyl chain of N-methylphenylglycine (Fig. 3B ). Significant fragments observed in the Q-TOF mass spectrometry corroborated the gross structure assignment of lipoglycopeptide 1 by NMR spectroscopy (Fig. 2) .
In regard to stereochemistry, amino acid analysis of lipoglycopeptide 1 revealed L and D configuration for the two alanines (34) . The coupling constant analysis of the sugar protons and ROESY data established the identity of the deoxy sugar as deoxy-α-mannose (Table 1 of the N-methyl-phenylglycine residue was tri-substituted rather than tetra-substituted, indicating that lipoglycopeptide 5 is a deshydroxy analog of lipoglycopeptide 1 (Table 2) .
Notably, the lack of the phenolic group ortho to the sugar substituent in lipoglycopeptide 5 resulted in the restoration of the sugar methyl to its normal frequency (δ H 0.64 in 1 vs
ppm in 5).
The structure of the remaining lipoglycopeptides 3, 4, 6, 7 and 8 was suggested by the high resolution ESIMS data shown in Table 3 Fig. 1) . The structures of glycopeptides 9 and 10 were fully supported by high-resolution mass measurement (Table 3 ) and NMR data (Table 4) . Specifically, in NMR spectra of glycopeptides 9 and 10, the N-methyl resonance of N-methylserine exhibited a significant up-field shift (~0.7 ppm) when compared to their acylated counterparts.
At the time of the completion of this work, a literature search revealed that this family of lipoglycopeptides is novel. Subsequently, we learned that structures of a similar family of lipopeptides, called arylomycins, have been disclosed in a conference proceeding (35) followed by a publication (36). The major structural difference is the absence of the sugar unit in arylomycins.
Determination of bacterial SPases I activity -As illustrated in Table 5 , all 8 compounds showed potent inhibitory activity against E. coli SPase I with IC 50 ranging from 0.11 to 0.19 µM. They also inhibited S. pneumoniae SPase I with IC 50 of 2.4-24.9 µM. The activity was further confirmed by the HPLC assay. As revealed by HPLC profiles, the intact peptide substrate has one peak with retention time of 5.45 min (Fig. 4A ). After incubation with SPase I, the substrate was specifically cleaved, two products with retention time of 4.1 and 4.9 min, respectively, were generated (Fig. 4B) . When a lipoglycopeptide was included in the reaction mixture, the cleavage of the peptide substrate was inhibited (Fig. 4C) , thus confirming the inhibitory activity.
Determination of mechanism of inhibition -Kinetic analysis with lipoglycopeptides 2, 5, 7 and 8 by HPLC assay revealed competitive inhibition with Ki ranging from 50-158 nM (Table 5) . Fig. 5 is an example of the Lineweaver-Burk plot for lipoglycopeptide 5.
Analysis demonstrated that increasing substrate concentration proportionally reduced the inhibition of SPase I activity by lipoglycopeptide 5 as determined by velocity changes.
Therefore, the mechanism of action of this compound is competitive with respect to the substrate. Similar kinetic analysis was also performed for compounds 2, 7 and 8, which also showed competitive mechanism (data not shown). demonstrated that the cells treated with lipoglycopeptides secreted less β-lactamase in the medium in a dose-dependent manner when compared to the control cells, and conversely, the activity of β-lactamase retained within the cells treated with lipopeptide was slightly higher than the control (Fig. 6 ), suggesting that these SPase I inhibitors indeed inhibit protein secretion within the bacterial cells.
Determination of anti-bacterial activity -
DISCUSSION
Proteases in general are divided into four classes according to their mechanism of action, and they are serine, cysteine, metallo-and aspartyl proteases. However, recent investigations have unambiguously demonstrated that SPase I is not a member of any of these four traditional classes. For example, it is not sensitive to any of the standard protease inhibitors (2, 3). The catalytic mechanism of the bacterial SPase I has been studied by site-directed mutagenesis using E. coli enzyme (15, 16) , Bacillus subtilis SipS (37) and S. pneumoniae enzyme (9) . In all these cases, a conserved serine and a conserved lysine were identified to be critical for enzymatic activity. These results suggest that SPases belong to a novel class of serine proteases that utilize a serine and a lysine to form a catalytic dyad. This serine/lysine catalytic dyad structure has been recently confirmed by the structure of E. coli SPase I in complex with 5S, 6S-penem (38).
This unique catalytic mechanism may explain the difficulty to identify effective SPase inhibitors and thus, to date, only β-lactams with moderate potency have been reported (19, 24, 25) . In the present study, we introduce a novel class of lipoglycopeptides as potent inhibitors of SPase I. These peptides have shown competitive inhibition of SPase I, with Ki ranging from 50-158 nM. Mechanistically, they blocked the bacterial protein secretion and inhibited the growth of both Gram-positive and Gram-negative bacteria.
These favorable biochemical and physiological properties place this class of compounds as potential candidates for further development as effective novel antibiotics.
Our work has shown that these lipoglycopeptides inhibit SPase I from both E. coli and S.
pneumoniae, but with different potency. In general, they are more potent against Gramnegative E. coli SPase I than Gram-positive S. pneumoniae enzyme (Table 5) Table 6 , the lipoglycopeptides showed MIC of 4-8 µM against E. coli EL683 strain, whereas these compounds had MIC >64 µM against wild type E. coli K12 strain.
Apparently, changing the outer membrane permeability of Gram-negative E. coli improved the antibacterial activity of these lipoglycopeptides. Therefore, the structure of these lipoglycopeptides needs to be optimized for better permeability to inhibit the growth of Gram-negative bacteria. In addition, these lipoglycopeptides also showed MIC of 8-32 µM against another E. coli Strain, EL744. EL744 is an E. coli K12 isogenic strain in which tolC, a component of an outer membrane efflux pump, was deleted (40). This implies that an intrinsic resistance to these lipoglycopeptides may exist via a multi-drug efflux system in E. coli. Further investigation to confirm this mechanism is needed. control-1 control-2 1 ug/ml 2 ug/ml 4 ug/ml 8 ug/ml 16 ug/ml 32 ug/ml
